7-octadecynoic acid is a lipid of Fatty Acyls (FA) class.
We collected disease MeSH terms mapped to the references associated with 7-octadecynoic acid
Authors | Title | Published | Journal | PubMed Link |
---|---|---|---|---|
Liu J et al. | Pressure-loaded MSCs during early osteodifferentiation promote osteoclastogenesis by increase of RANKL/OPG ratio. | 2009 | Ann Biomed Eng | pmid:19148752 |
Olivares-Navarrete R et al. | Osteoblast lineage cells can discriminate microscale topographic features on titanium-aluminum-vanadium surfaces. | 2014 | Ann Biomed Eng | pmid:25227453 |
Schlieper G et al. | Analysis of calcifications in patients with coral reef aorta. | 2010 | Ann Vasc Surg | pmid:20144533 |
Buckley KA and Fraser WD | Receptor activator for nuclear factor kappaB ligand and osteoprotegerin: regulators of bone physiology and immune responses/potential therapeutic agents and biochemical markers. | 2002 | Ann. Clin. Biochem. | pmid:12564836 |
Hofbauer LC | Pathophysiology of RANK ligand (RANKL) and osteoprotegerin (OPG). | 2006 | Ann. Endocrinol. (Paris) | pmid:16639364 |
Quemerais-Durieu MA et al. | [Therapeutic innovation in osteoporosis (antisclerostin antibody and denosumab)]. | 2011 | Ann. Endocrinol. (Paris) | pmid:22008272 |
Perifanis V et al. | Effect of zoledronic acid on markers of bone turnover and mineral density in osteoporotic patients with beta-thalassaemia. | 2007 | Ann. Hematol. | pmid:17013645 |
Christoforidis A et al. | Increased osteoclastic activity as shown by increased sRANK-L/OPG ratio in boys with hemophilia. | 2010 | Ann. Hematol. | pmid:20084381 |
Korostishevsky M et al. | Anthropometric and bone-related biochemical factors are associated with different haplotypes of ANKH locus. | 2008 Sep-Oct | Ann. Hum. Biol. | pmid:18821330 |
Kwan JS et al. | Heritability of serum osteoprotegerin. | 2011 | Ann. Hum. Genet. | pmid:21762114 |
Vistoropsky Y et al. | Osteoprotegerin plasma levels are strongly associated with polymorphisms in human homologue of the mouse progressive ankylosis (ANKH) gene. | 2007 | Ann. Hum. Genet. | pmid:17147692 |
Priyadarshi S et al. | Genetic association and altered gene expression of osteoprotegerin in otosclerosis patients. | 2015 | Ann. Hum. Genet. | pmid:25998045 |
Dovio A et al. | [Pathophysiological significance and clinical utility of circulating osteoprotegerin]. | 2004 Jan-Mar | Ann. Ital. Med. Int. | pmid:15176704 |
Schinke T et al. | Molecular determinants of arterial calcification. | 1998 | Ann. Med. | pmid:9920355 |
MacNee W | Systemic inflammatory biomarkers and co-morbidities of chronic obstructive pulmonary disease. | 2013 | Ann. Med. | pmid:23110517 |
Montagnana M et al. | The role of osteoprotegerin in cardiovascular disease. | 2013 | Ann. Med. | pmid:23110639 |
Weitzmann MN and Pacifici R | T cells: unexpected players in the bone loss induced by estrogen deficiency and in basal bone homeostasis. | 2007 | Ann. N. Y. Acad. Sci. | pmid:18083938 |
Wimalawansa SJ | Rationale for using nitric oxide donor therapy for prevention of bone loss and treatment of osteoporosis in humans. | 2007 | Ann. N. Y. Acad. Sci. | pmid:18056048 |
Lin-Su K and New MI | Effects of adrenal steroids on the bone metabolism of children with congenital adrenal hyperplasia. | 2007 | Ann. N. Y. Acad. Sci. | pmid:18056052 |
Leibbrandt A and Penninger JM | RANK/RANKL: regulators of immune responses and bone physiology. | 2008 | Ann. N. Y. Acad. Sci. | pmid:19076348 |
Glass DA and Karsenty G | Canonical Wnt signaling in osteoblasts is required for osteoclast differentiation. | 2006 | Ann. N. Y. Acad. Sci. | pmid:16831912 |
Whyte MP | Paget's disease of bone and genetic disorders of RANKL/OPG/RANK/NF-kappaB signaling. | 2006 | Ann. N. Y. Acad. Sci. | pmid:16831914 |
Zallone A | Direct and indirect estrogen actions on osteoblasts and osteoclasts. | 2006 | Ann. N. Y. Acad. Sci. | pmid:16831916 |
Liu XH et al. | Interactive effect of interleukin-6 and prostaglandin E2 on osteoclastogenesis via the OPG/RANKL/RANK system. | 2006 | Ann. N. Y. Acad. Sci. | pmid:16831922 |
Matsumoto T and Abe M | Bone destruction in multiple myeloma. | 2006 | Ann. N. Y. Acad. Sci. | pmid:16831932 |
Brunetti G et al. | The role of OPG/TRAIL complex in multiple myeloma: the OPG/TRAIL complex in an in vitro osteoclastogenesis model derived from human multiple myeloma-bone disease. | 2006 | Ann. N. Y. Acad. Sci. | pmid:16831934 |
Boumans MJ et al. | Rituximab abrogates joint destruction in rheumatoid arthritis by inhibiting osteoclastogenesis. | 2012 | Ann. Rheum. Dis. | pmid:22072013 |
Sagar DR et al. | Osteoprotegerin reduces the development of pain behaviour and joint pathology in a model of osteoarthritis. | 2014 | Ann. Rheum. Dis. | pmid:23723320 |
Castellino G et al. | Is there any role for tumour necrosis factor related apoptosis inducing ligand-osteoprotegerin (TRAIL-OPG) interaction in rheumatoid arthritis? | 2008 | Ann. Rheum. Dis. | pmid:18621972 |
Itonaga I et al. | Effect of osteoprotegerin and osteoprotegerin ligand on osteoclast formation by arthroplasty membrane derived macrophages. | 2000 | Ann. Rheum. Dis. | pmid:10627423 |
Skoumal M et al. | Serum osteoprotegerin but not receptor activator of NF-kappaB ligand correlates with Larsen score in rheumatoid arthritis. | 2004 | Ann. Rheum. Dis. | pmid:14722219 |
Gengenbacher M et al. | Infliximab inhibits bone resorption by circulating osteoclast precursor cells in patients with rheumatoid arthritis and ankylosing spondylitis. | 2008 | Ann. Rheum. Dis. | pmid:17720725 |
Ruocco MG and Karin M | IKK{beta} as a target for treatment of inflammation induced bone loss. | 2005 | Ann. Rheum. Dis. | pmid:16239395 |
Smith MD et al. | Microarchitecture and protective mechanisms in synovial tissue from clinically and arthroscopically normal knee joints. | 2003 | Ann. Rheum. Dis. | pmid:12634226 |
Crotti TN et al. | Receptor activator NF-kappaB ligand (RANKL) expression in synovial tissue from patients with rheumatoid arthritis, spondyloarthropathy, osteoarthritis, and from normal patients: semiquantitative and quantitative analysis. | 2002 | Ann. Rheum. Dis. | pmid:12429533 |
Dai SM et al. | Interleukin (IL) 18 stimulates osteoclast formation through synovial T cells in rheumatoid arthritis: comparison with IL1 beta and tumour necrosis factor alpha. | 2004 | Ann. Rheum. Dis. | pmid:15479886 |
Wagner EF and Matsuo K | Signalling in osteoclasts and the role of Fos/AP1 proteins. | 2003 | Ann. Rheum. Dis. | pmid:14532157 |
van Tuyl LH et al. | Baseline RANKL:OPG ratio and markers of bone and cartilage degradation predict annual radiological progression over 11 years in rheumatoid arthritis. | 2010 | Ann. Rheum. Dis. | pmid:20525836 |
Pathan E et al. | Efficacy and safety of apremilast, an oral phosphodiesterase 4 inhibitor, in ankylosing spondylitis. | 2013 | Ann. Rheum. Dis. | pmid:22984171 |
Feige U | Osteoprotegerin. | 2001 | Ann. Rheum. Dis. | pmid:11890662 |
O' Gradaigh D et al. | Joint erosion in rheumatoid arthritis: interactions between tumour necrosis factor alpha, interleukin 1, and receptor activator of nuclear factor kappaB ligand (RANKL) regulate osteoclasts. | 2004 | Ann. Rheum. Dis. | pmid:15020327 |
Jones DH et al. | Role of RANKL and RANK in bone loss and arthritis. | 2002 | Ann. Rheum. Dis. | pmid:12379618 |
González-Alvaro I et al. | Baseline serum RANKL levels may serve to predict remission in rheumatoid arthritis patients treated with TNF antagonists. | 2007 | Ann. Rheum. Dis. | pmid:17666448 |
Gravallese EM | Bone destruction in arthritis. | 2002 | Ann. Rheum. Dis. | pmid:12379632 |
Vis M et al. | Evaluation of bone mineral density, bone metabolism, osteoprotegerin and receptor activator of the NFkappaB ligand serum levels during treatment with infliximab in patients with rheumatoid arthritis. | 2006 | Ann. Rheum. Dis. | pmid:16606653 |
Bao BY et al. | Clinical significance of tumor necrosis factor receptor superfamily member 11b polymorphism in prostate cancer. | 2010 | Ann. Surg. Oncol. | pmid:20204532 |
Kress DC | Invited commentary. | 2013 | Ann. Thorac. Surg. | pmid:23992687 |
Cao H et al. | Preoperative serum soluble receptor activator of nuclear factor-κB ligand and osteoprotegerin predict postoperative atrial fibrillation in patients undergoing cardiac valve surgery. | 2013 | Ann. Thorac. Surg. | pmid:23870696 |
Walsh MC et al. | Osteoimmunology: interplay between the immune system and bone metabolism. | 2006 | Annu. Rev. Immunol. | pmid:16551243 |
Theill LE et al. | RANK-L and RANK: T cells, bone loss, and mammalian evolution. | 2002 | Annu. Rev. Immunol. | pmid:11861618 |
Pettersen I et al. | Osteoprotegerin is expressed in colon carcinoma cells. | 2005 Nov-Dec | Anticancer Res. | pmid:16309167 |
Katopodis H et al. | MG-63 osteoblast-like cells enhance the osteoprotegerin expression of PC-3 prostate cancer cells. | 2009 | Anticancer Res. | pmid:19846944 |
Zojer N et al. | Bisphosphonate treatment does not affect serum levels of osteoprotegerin and RANKL in hypercalcemic cancer patients. | 2005 Sep-Oct | Anticancer Res. | pmid:16101188 |
Owen S et al. | Expression profile of receptor activator of nuclear-κB (RANK), RANK ligand (RANKL) and osteoprotegerin (OPG) in breast cancer. | 2013 | Anticancer Res. | pmid:23267146 |
Brown TT et al. | Bone turnover, osteoprotegerin/RANKL and inflammation with antiretroviral initiation: tenofovir versus non-tenofovir regimens. | 2011 | Antivir. Ther. (Lond.) | pmid:22024522 |
Belibasakis GN et al. | Cytolethal distending toxin upregulates RANKL expression in Jurkat T-cells. | 2008 | APMIS | pmid:18754324 |
Krajewski AC et al. | Influence of lipopolysaccharide and interleukin-6 on RANKL and OPG expression and release in human periodontal ligament cells. | 2009 | APMIS | pmid:19775343 |
Esteghamati A et al. | Association of osteoprotegerin with peripheral artery disease in patients with type 2 diabetes. | 2015 Aug-Sep | Arch Cardiovasc Dis | pmid:26184866 |
Marques EA et al. | Response of bone mineral density, inflammatory cytokines, and biochemical bone markers to a 32-week combined loading exercise programme in older men and women. | 2013 Sep-Oct | Arch Gerontol Geriatr | pmid:23623588 |
Esteghamati A et al. | Serum osteoprotegerin in relation to metabolic status, severity, and estimated risk of subsequent coronary heart disease. | 2014 | Arch Iran Med | pmid:25204474 |
Lee JS et al. | Changes in serum levels of receptor activator of nuclear factor-kappaB ligand, osteoprotegerin, IL-6 and TNF-alpha in patients with a concomitant head injury and fracture. | 2009 | Arch Orthop Trauma Surg | pmid:18427820 |
Del Fattore A et al. | Osteoclast receptors and signaling. | 2008 | Arch. Biochem. Biophys. | pmid:18237538 |
Merewether LA et al. | Development of disulfide peptide mapping and determination of disulfide structure of recombinant human osteoprotegerin chimera produced in Escherichia coli. | 2000 | Arch. Biochem. Biophys. | pmid:10683254 |
Boyce BF and Xing L | Functions of RANKL/RANK/OPG in bone modeling and remodeling. | 2008 | Arch. Biochem. Biophys. | pmid:18395508 |
Helfrich MH and Hocking LJ | Genetics and aetiology of Pagetic disorders of bone. | 2008 | Arch. Biochem. Biophys. | pmid:18359282 |
Kuroyanagi G et al. | Resveratrol suppresses prostaglandin F(2α)-induced osteoprotegerin synthesis in osteoblasts: inhibition of the MAP kinase signaling. | 2014 | Arch. Biochem. Biophys. | pmid:24333336 |
Kim H et al. | Association between endometriosis and polymorphisms in tumor necrosis factor-related apoptosis-inducing ligand (TRAIL), TRAIL receptor and osteoprotegerin genes and their serum levels. | 2012 | Arch. Gynecol. Obstet. | pmid:22392486 |
Eren MA et al. | Association of parity with osteoprotegerin levels and atherosclerosis. | 2013 | Arch. Gynecol. Obstet. | pmid:23287888 |
Kraj M et al. | Correlation of osteoprotegerin and sRANKL concentrations in serum and bone marrow of multiple myeloma patients. | 2005 Sep-Oct | Arch. Immunol. Ther. Exp. (Warsz.) | pmid:16314829 |
Åšwierkot J et al. | Assessment of the Effect of Methotrexate Therapy on Bone Metabolism in Patients with Rheumatoid Arthritis. | 2015 | Arch. Immunol. Ther. Exp. (Warsz.) | pmid:25837853 |
Zdzisińska B et al. | Dysregulation of the receptor activator of NF-kappaB ligand and osteoprotegerin production influence the apoptosis of multiple myeloma patients' bone marrow stromal cells co-cultured with myeloma cells. | 2010 | Arch. Immunol. Ther. Exp. (Warsz.) | pmid:20157786 |
Ugur-Altun B and Altun A | Circulating leptin and osteoprotegerin levels affect insulin resistance in healthy premenopausal obese women. | 2007 | Arch. Med. Res. | pmid:17923273 |
Kerr NM et al. | Ocular manifestations of juvenile Paget disease. | 2010 | Arch. Ophthalmol. | pmid:20547946 |
Tripuwabhrut P et al. | Effect of compressive force on human osteoblast-like cells and bone remodelling: an in vitro study. | 2013 | Arch. Oral Biol. | pmid:23583016 |
Wada Y et al. | Enamel matrix derivative neutralized the effect of lipopolysaccharide on osteoprotegerin and receptor activator of nuclear factor kappa B ligand expression of osteoblasts. | 2009 | Arch. Oral Biol. | pmid:19201394 |
Zhang D et al. | The expression of osteoprotegerin and the receptor activator of nuclear factor kappa B ligand in human periodontal ligament cells cultured with and without 1alpha,25-dihydroxyvitamin D3. | 2004 | Arch. Oral Biol. | pmid:14693199 |
Nonaka CF et al. | Immunohistochemical analysis of bone resorption regulators (RANKL and OPG), angiogenic index, and myofibroblasts in syndrome and non-syndrome odontogenic keratocysts. | 2012 | Arch. Oral Biol. | pmid:21871606 |
Dalla-Bona DA et al. | Cementoblast response to low- and high-intensity ultrasound. | 2008 | Arch. Oral Biol. | pmid:18163974 |
Wen Y et al. | Application of eGFP to label human periodontal ligament stem cells in periodontal tissue engineering. | 2012 | Arch. Oral Biol. | pmid:22410147 |
Mayahara K et al. | Osteoblasts stimulate osteoclastogenesis via RANKL expression more strongly than periodontal ligament cells do in response to PGE(2). | 2012 | Arch. Oral Biol. | pmid:22884709 |
Liao C and Hua Y | Effect of hydrogen sulphide on the expression of osteoprotegerin and receptor activator of NF-κB ligand in human periodontal ligament cells induced by tension-force stimulation. | 2013 | Arch. Oral Biol. | pmid:24200305 |
Luvizuto ER et al. | Histomorphometric analysis and immunolocalization of RANKL and OPG during the alveolar healing process in female ovariectomized rats treated with oestrogen or raloxifene. | 2010 | Arch. Oral Biol. | pmid:19948337 |
Wattanaroonwong N et al. | Oestrogen inhibits osteoclast formation induced by periodontal ligament fibroblasts. | 2011 | Arch. Oral Biol. | pmid:21035111 |
Jacobs C et al. | Osteogenic differentiation of periodontal fibroblasts is dependent on the strength of mechanical strain. | 2013 | Arch. Oral Biol. | pmid:23422327 |
Bastos MF et al. | Effects of Cachaça, a typical Brazilian alcoholic beverage, on alveolar bone loss and density: a study in peripubertal rats. | 2014 | Arch. Oral Biol. | pmid:24183604 |
Nishigaki M et al. | β-cryptoxanthin regulates bone resorption related-cytokine production in human periodontal ligament cells. | 2013 | Arch. Oral Biol. | pmid:23452546 |
de Moraes M et al. | Comparative immunohistochemical expression of RANK, RANKL and OPG in radicular and dentigerous cysts. | 2011 | Arch. Oral Biol. | pmid:21683340 |
Sheng ZF et al. | OPG knockout mouse teeth display reduced alveolar bone mass and hypermineralization in enamel and dentin. | 2010 | Arch. Oral Biol. | pmid:20233613 |
Tazoe M et al. | Involvement of p38MAP kinase in bone morphogenetic protein-4-induced osteoprotegerin in mouse bone-marrow-derived stromal cells. | 2003 | Arch. Oral Biol. | pmid:12828991 |
Luvizuto ER et al. | Raloxifene therapy inhibits osteoclastogenesis during the alveolar healing process in rats. | 2011 | Arch. Oral Biol. | pmid:21536255 |
de Souza JA et al. | Expression of suppressor of cytokine signaling 1 and 3 in ligature-induced periodontitis in rats. | 2011 | Arch. Oral Biol. | pmid:21511249 |
Kim SJ et al. | Compressive stress induced the up-regulation of M-CSF, RANKL, TNF-α expression and the down-regulation of OPG expression in PDL cells via the integrin-FAK pathway. | 2013 | Arch. Oral Biol. | pmid:23219295 |
Tang X and Meng H | Osteogenic induction and 1,25-dihydroxyvitamin D3 oppositely regulate the proliferation and expression of RANKL and the vitamin D receptor of human periodontal ligament cells. | 2009 | Arch. Oral Biol. | pmid:19464673 |
Inubushi T et al. | Lactoferrin inhibits infection-related osteoclastogenesis without interrupting compressive force-related osteoclastogenesis. | 2014 | Arch. Oral Biol. | pmid:24370195 |
Wise GE et al. | Inhibition of osteoclastogenesis by the secretion of osteoprotegerin in vitro by rat dental follicle cells and its implications for tooth eruption. | 2002 | Arch. Oral Biol. | pmid:11839361 |
Kadkhodazadeh M et al. | Analysis of RANKL gene polymorphism (rs9533156 and rs2277438) in Iranian patients with chronic periodontitis and periimplantitis. | 2013 | Arch. Oral Biol. | pmid:23177932 |
Lee MH et al. | The effect of surface microgrooves and anodic oxidation on the surface characteristics of titanium and the osteogenic activity of human periodontal ligament cells. | 2013 | Arch. Oral Biol. | pmid:22717323 |
Heinrich J et al. | CSF-1, RANKL and OPG regulate osteoclastogenesis during murine tooth eruption. | 2005 | Arch. Oral Biol. | pmid:16137499 |
Neves JS et al. | Immunolocalization of CSF-1, RANKL and OPG in the enamel-related periodontium of the rat incisor and their implications for alveolar bone remodeling. | 2009 | Arch. Oral Biol. | pmid:19419711 |
Ramirez-Yanez GO and Symons AL | Prostaglandin E2 affects osteoblast biology in a dose-dependent manner: an in vitro study. | 2012 | Arch. Oral Biol. | pmid:22480456 |